KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other Accumulated Expenses (2020 - 2025)

Royalty Pharma (RPRX) has disclosed Other Accumulated Expenses for 6 consecutive years, with $53.2 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 22.5% to $53.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $53.2 million through Dec 2025, down 22.5% year-over-year, with the annual reading at $53.2 million for FY2025, 22.5% down from the prior year.
  • Other Accumulated Expenses hit $53.2 million in Q4 2025 for Royalty Pharma, up from $3.1 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $97.5 million in Q2 2024 to a low of $3.1 million in Q2 2025.
  • Historically, Other Accumulated Expenses has averaged $28.4 million across 5 years, with a median of $12.4 million in 2022.
  • Biggest five-year swings in Other Accumulated Expenses: surged 503.08% in 2024 and later crashed 96.85% in 2025.
  • Year by year, Other Accumulated Expenses stood at $4.3 million in 2021, then soared by 187.44% to $12.4 million in 2022, then fell by 8.27% to $11.4 million in 2023, then soared by 503.08% to $68.6 million in 2024, then decreased by 22.5% to $53.2 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for RPRX at $53.2 million in Q4 2025, $3.1 million in Q3 2025, and $3.1 million in Q2 2025.